ストックスクリーナーアプリを入手
21.17
2.47%
0.51
アフターアワーズ：
21.04
-0.13
-0.61%
前日終値:
$20.66
開ける：
$20.71
24時間の取引高:
2.70M
Relative Volume:
1.98
時価総額：
$2.65B
収益：
$376.07M
当期純損益:
$-16.14M
株価収益率:
-151.32
EPS:
-0.1399
ネットキャッシュフロー:
$-16.31M
1週間 パフォーマンス:
-9.34%
1か月 パフォーマンス:
-13.98%
6か月 パフォーマンス:
-12.63%
1年 パフォーマンス:
+56.64%
1日の値動き範囲:
$20.25
$21.36
1週間の範囲:
$20.19
$24.27
52週間の値動き範囲:
$12.72
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
名前
Arcutis Biotherapeutics Inc
セクター
電話
805-418-5006
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
21.17 | 2.58B | 376.07M | -16.14M | -16.31M | -0.1399 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.34B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.96B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.51B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.89B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | 開始されました | Goldman | Neutral |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-03 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-26 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-10-13 | ダウングレード | Goldman | Buy → Neutral |
| 2022-09-07 | 開始されました | Needham | Buy |
| 2022-03-17 | 開始されました | Goldman | Buy |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-05-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | アップグレード | Goldman | Neutral → Buy |
| 2020-10-08 | 開始されました | Truist | Buy |
| 2020-02-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 開始されました | Cowen | Outperform |
| 2020-02-25 | 開始されました | Goldman | Neutral |
| 2020-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
40 new Arcutis hires receive stock units and options under Nasdaq rule - Stock Titan
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Prudential Financial (ARQT) reports 5.30M-share stake; Jennison holds 4.98M - Stock Titan
ARQT SEC FilingsArcutis Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Arcutis Biotherapeutics (ARQT) Reports Strong Q1 2026 Earnings w - GuruFocus
ARQT Reiterates by Needham -- Price Target Maintained at $36.00 - GuruFocus
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Cuts Target Price to $34 - Moomoo
Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis outlines $480M-$495M 2026 revenue guidance while expanding ZORYVE sales teams - MSN
Arcutis Biotherapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-05-07 - Seeking Alpha
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $31,661 in stock By Investing.com - Investing.com Australia
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock By Investing.com - Investing.com India
[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com
Arcutis Q1 2026 slides: revenue surges 65% as ZORYVE gains share - Investing.com India
Arcutis Biotherapeutics CMO sells $16,149 in shares By Investing.com - Investing.com India
Arcutis Biotherapeutics Q1 Earnings Call Highlights - Yahoo Finance
Arcutis Biotherapeutics CEO Todd Watanabe sells $74,892 in stock By Investing.com - Investing.com India
Arcutis Biotherapeutics CEO Todd Watanabe sells $74,892 in stock - Investing.com
Arcutis Biotherapeutics CMO sells $16,149 in shares - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 sees revenue beat, EPS miss - Investing.com
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $31,661 in stock - Investing.com UK
Arcutis Biotherapeutics (ARQT) officer sells 684 shares to cover RSU taxes - Stock Titan
Arcutis (ARQT) CFO sells 1,341 shares to cover RSU tax obligations - Stock Titan
Arcutis Biotherapeutics (ARQT) insider sells 3,172 shares for RSU taxes - Stock Titan
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Arcutis Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ARCUTIS BIOTHERAPEUTICS ($ARQT) Releases Q1 2026 Earnings - Quiver Quantitative
Jennison holds 4.98M shares in Arcus Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (ARQT) grows ZORYVE sales and narrows Q1 2026 loss - Stock Titan
Arcutis seeks infant eczema expansion after $105M ZORYVE quarter - Stock Titan
ZORYVE fuels Arcutis (NASDAQ: ARQT) Q1 2026 $105M revenue and cash-flow positive quarter - Stock Titan
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update - Caledonian Record
Arcutis Biotherapeutics 1Q Loss/Shr 9c >ARQT - Moomoo
Arcutis earnings on deck as profitability path faces scrutiny By Investing.com - Investing.com India
Arcutis earnings on deck as profitability path faces scrutiny - Investing.com
Trading Systems Reacting to (ARQT) Volatility - Stock Traders Daily
Arcutis director Howard Welgus sells $164,219 in company stock By Investing.com - Investing.com Canada
Arcutis director Howard Welgus sells $164,219 in company stock - Investing.com
Arcutis Biotherapeutics (ARQT) director sells 7,144 shares under 10b5-1 plan - Stock Titan
ARQT Stock Price, Quote & Chart | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Director sale: Arcutis Biotherapeutics (NASDAQ: ARQT) plans to sell 684 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) files to sell 1,341 vested shares via Merrill Lynch - Stock Titan
3,172-Share Form 144 Filed by Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) reports vesting and insider sales in Form 144 - Stock Titan
Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
UBS Group AG Boosts Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Kornitzer Capital Management Inc. KS Takes Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Howard Welgus sells 30,000 ARQT shares (NASDAQ: ARQT) across three dates - Stock Titan
Arcutis Biotherapeutics Inc (ARQT) 財務データ
収益
当期純利益
現金流量
EPS
11.97%
3.48%
大文字化:
|
ボリューム (24 時間):